When you purchase a pack of cigarettes in the United States, the regulations governing what is in that pack depend significantly on where it was made.
Domestic tobacco manufacturers are required to register with the FDA, submit product listings that document each product's ingredients and design, follow current Good Manufacturing Practice standards, and report adverse events. Foreign manufacturers who want to sell tobacco products in the United States have not been subject to the same requirements — because while Congress gave the FDA authority to require foreign registration in Section 905(h) of the Tobacco Control Act, the agency had never issued the implementing regulations to make that requirement operative. Until now.
The FDA proposed a rule on June 26, 2026, titled "Establishment Registration and Product Listing for Tobacco Products," that would substantially level the regulatory playing field between domestic and foreign tobacco manufacturers operating in the United States market. Public comments are open through September 14, 2026.
Why This Matters
The Family Smoking Prevention and Tobacco Control Act of 2009 gave the FDA authority to regulate tobacco products. But the FDA's regulatory reach over foreign manufacturers has been more limited than over domestic ones in practice — a gap that consumer advocates say has allowed some foreign-manufactured tobacco products to reach American consumers without the same level of safety and transparency scrutiny applied to domestically made equivalents.
This matters because the U.S. tobacco market includes products from a wide range of international manufacturers — cigarettes, cigars, smokeless tobacco, and increasingly electronic nicotine delivery systems manufactured in Asia, Europe, and other regions. The FDA has taken recent record-breaking seizures of unauthorized e-cigarettes at U.S. ports, nearly all of which are manufactured overseas — making this regulatory asymmetry a particularly significant public health issue in the current market.
What the Proposed Rule Would Do
The FDA's proposed rule would require foreign tobacco manufacturers to:
- Register directly with the FDA in the same way domestic manufacturers are required to, creating a centralized record of every foreign manufacturer whose products are sold in the United States
- Submit product listings for each tobacco product sold in the U.S. market, documenting ingredients, product design, and any changes — updated annually for registrations and twice yearly for product listings
- Submit detailed product information , including nicotine concentration and source, characterizing flavors, package sizes and types, and for e-cigarettes: e-liquid volume, battery capacity, and wattage
- Be subject to FDA facility inspections — making foreign manufacturers subject to on-site oversight for the first time
- Be subject to FDA enforcement action — including product removal from the U.S. market — if compliance with U.S. standards cannot be verified
The rule would also address the import pathway: tobacco products from non-compliant foreign manufacturers could be refused entry into the United States if the manufacturer fails to meet the proposed registration and compliance requirements.
Why the Gap Existed in the First Place
The gap between domestic and foreign tobacco manufacturer oversight reflects a broader challenge in U.S. consumer product regulation: the FDA's authority to physically inspect foreign manufacturing facilities is more limited than its authority over domestic facilities, and enforcement against a non-compliant manufacturer located overseas is logistically complex.
As the National Law Review analysis of the proposed rule explains, "Congress created a pathway for FDA to require foreign tobacco manufacturing establishment registration in Section 905(h), and FDA has finally proposed the implementing regulations necessary to make that requirement operative."
What Doctors and Experts Say
"All companies selling tobacco products in the United States should play by the same rules," said Bret Koplow, acting director of the FDA's Center for Tobacco Products. "The FDA is working hard to close the gap between domestic and foreign companies, level the playing field for American businesses, and ensure that all manufacturers are held to the same standards."
Public health researchers and tobacco control advocates have consistently pointed to the foreign manufacturer gap as a risk factor for tobacco products reaching U.S. consumers with undisclosed ingredients, inconsistent quality standards, or potential contamination that would not pass domestic manufacturing scrutiny. The specific concern is particularly acute for the growing market for novel tobacco and nicotine products — particularly certain electronic nicotine delivery systems — whose manufacturers may have less established regulatory compliance histories.
What the Evidence Shows — and What It Does Not
The proposed rule addresses a documented regulatory structure gap — the difference in what the FDA legally requires of domestic versus foreign manufacturers. As the FDA acknowledges in the proposed rule itself, "because it has not yet issued such regulations, foreign owners and operators are not currently required to register their establishments or list tobacco products."
What is well-documented: domestic tobacco manufacturers are subject to product listing, ingredient disclosure, and facility registration requirements that foreign manufacturers have not consistently faced to the same degree. The proposed rule would, if finalized, close this documented gap in regulatory structure. Note that registration and product listing would not equal FDA marketing authorization — products subject to premarket review requirements would still need valid FDA authorization to be legally marketed in the United States.
What You Can Do Now
If you use tobacco products and want to understand what regulatory standards apply to your specific product, check the FDA's tobacco product database for product listings submitted under the Tobacco Control Act.
Submit a comment on the proposed rule during the public comment period, open through September 14, 2026. Search for the docket titled "Establishment Registration and Product Listing for Tobacco Products."
If you want to quit tobacco, the CDC's Tips From Former Smokers campaign and the SAMHSA National Helpline (1-800-662-4357) provide free cessation support.
The Bottom Line
A regulatory asymmetry has historically allowed foreign tobacco manufacturers to sell products in the United States market under less direct FDA oversight than domestic manufacturers face. The FDA's June 26, 2026 proposed rule would require foreign manufacturers to register, submit detailed product listings, meet U.S. manufacturing standards, and be subject to U.S. facility inspections and enforcement action — creating a more level regulatory playing field. Public comments are accepted through September 14, 2026.
